In West/West Central Africa, CRF02_AG is the most prevalent HIV-1 strain and circulates in the milieu of rare subtypes, circulating recombinant forms (CRFs), and unique recombinant forms (URFs). The molecular complexity of HIV-1 epidemics in this region and the need to extensively sample large populations, such as in the case of vaccine trials, pose seemingly conflicting requirements between full-genome sequencing and high-throughput low-resolution assays. Here we describe the development and evaluation of a multiregion hybridization assay (MHAcrf02) for the efficient genotyping of CRF02_AG in West/West Central Africa. Subtype A, G, and CRF02_AG-specific fluorescent probes were designed flanking five recombination breakpoints in CRF02_AG and were used in real-time PCRs. A panel representing West/West Central African HIV-1 genetic diversity was evaluated by MHAcrf02. The sample set, previously characterized by full-genome sequencing, included CRF02_AG and CRF02_AG-containing recombinants (n 5 28), other subtypes, CRFs, and URFs (n 5 34). DNA from peripheral blood mononuclear cells, cocultures, and plasmids was used as template. When the patterns of probe reactivity were evaluated. CRF02_AG was identified with a 100% specificity and sensitivity. In conclusion, MHAcrf02 will permit more efficient characterization of HIV-1 in West/West Central Africa, where CRF02_AG is an important strain. Together with other regional genotyping assays MHAcrf02 will contribute to the development of a global picture of HIV-1 diversity and geographic distribution, providing a strong foundation for intervention, including vaccine development. 521 
INTRODUCTION T
HE HIV-1 PANDEMIC is characterized by the circulation of multiple genetic subtypes and many more intersubtype recombinants. [1] [2] [3] [4] Some of the recombinants have been found in only one patient [i.e., unique recombinant forms (URFs)], while others have widely spread in populations [i.e., circulating recombinant forms (CRFs)].
Extensive HIV-1 genetic diversity is represented in the strains that have been found in West/West Central Africa. In this region, CRF02_AG, a recombinant with a complex mosaic genomic structure, is the predominant strain, circulating in the milieu of many other subtypes, CRFs, and URFs. Based on previous reports, the proportion of HIV-1 infections with CRF02_AG ranges from 95 to 50% in different West/West Central African countries. Although the surveillance has not been systematic, and various genotyping approaches have been used with variable power to discriminate the CRF02_AG from other forms, it appears that CRF02_AG reaches its highest proportion of strains in the far West, with a gradual decrease to 50% or less in Central Africa. Another important finding has been that no single other clade accounted for the rest of the HIV-1 cases. [6] [7] [8] 11, 12, 19, [23] [24] [25] CRF02_AG is typically embedded in epidemics with a very complex mixture of rare subtypes and other recombinants. This has also led to the emergence of "second-generation" recombinants between the CRF and the other clades. 7, 28, 29 CRF02_AG is one of six globally prevalent HIV-1 strains [1] [2] [3] [4] and, accordingly, it has been selected for use in candidate HIV-1 vaccines. In the context of cohort development for interventions, there is a great need for a high-throughput genotyping tool that can clearly describe the molecular picture in the region. There seem to be conflicting methodological requirements for such an assay. On the one hand, it should be able to distinguish between CRF02_AG and related strains, and all other clades circulating in the region (including A/G recombinants not related to CRF02_AG). Currently, this can be achieved only by full-genome sequencing, a low-throughput and expensive technique. [30] [31] [32] On the other hand, genotyping of large cohorts can be assessed only by high-throughput tests, which have the drawback of low genetic resolution. Partial sequencing and heteroduplex mobility assay (HMA) are among the latter genotyping tools that have been applied in the study of CRF02_AG epidemics. 5, 6, 8, 10, 12, 25, [33] [34] [35] [36] A novel group of regional genotyping tests, the multiregion hybridization assays (MHAs), seems to bridge this methodological gap. 37 These assays are based on the hybridization of clade-specific fluorescent probes in a real-time PCR. MHAs are being used to describe complex epidemics, each tailored to the limited genetic diversity in the regions: subtypes A, C, and D in East Africa, 37 B and F in South America, 38 and B, C, and CRF01_AE in Southeast Asia, 39 respectively. Utilizing a similar MHA approach, we present the development of MHAcrf02, a high-throughput genotyping tool for the study of CRF02_AG in the West/West Central African HIV-1 epidemics. The simultaneous assessment of different HIV-1 genomic regions by a real-time PCR-based technique confers a high sensitivity and specificity to the assay, which make it suit-KIJAK ET AL. 522
FIG. 1.
Samples employed in the development of MHAcrf02. (a) List of the genotypes of the specimens, their country of origin, and type of sample. The CRF02_AG genomic content was 80% for CAM2339SA, 75% for CAM1590LE, 65% for CAM0190MA, 55% for CAM1901LE, 90% for CAM3228MN, and 40% for CAM1807LE. Unique recombinants contained subtypes A, D, F2, G, and CRF01_AE. Accession numbers of newly and previously reported sequences are listed in Materials and Methods. (b) Neighbor-joining tree based on full-length sequences of subtype A, G, D, F2, CRF02_AG, CRF11_cpx, and CRF13_cpx strains. The tree was built using Kimura two-parameter distance method (transition/transversion 5 2). 45 Strains studied by MHAcrf02 are shown as (j ] and reference sequences are shown as (u ) . Bootstrap values supporting clade-defining nodes are shown (over 100 replicates). (c) Neighbor-joining tree of CRF02_AG-containing recombinants and unique recombinant forms, represented as (d ) and (m ), respectively. able for the support of population-based interventions in the region, including the development of HIV-1 vaccines.
MATERIALS AND METHODS

Samples
In the development of the MHAcrf02, a panel of 62 samples, from which a virtually full-length sequence had been obtained, was used. Samples were chosen so that they represent the HIV-1 genetic diversity in West/West Central Africa, and included CRF02_AG, subtypes A, D, F2, and G, CRF11_cpx, CRF13_cpx, and URFs (Fig. 1a) . CRF02_AG-containing second-generation recombinants where also represented in the panel. Samples were collected mainly in Cameroon, and specimens from Kenya, Tanzania, Uganda, and Djibouti were also used. Depending on availability, primary peripheral blood mononuclear cells (PBMCs), cocultures, or nearly full-length HIV-1 genomes cloned in plasmids (TOPO-TA vectors, Invitrogen, Carlsbad, CA), were employed.
PBMC DNA was extracted using the MagnaPure robotic nucleic acid extraction procedure (Roche Diagnostics Corp., Indianapolis, IN), following the manufacturer's instructions. Coculture and plasmid DNA were extracted manually using QIAamp DNA and QIAGEN Plasmid kits (Qiagen Inc., Valencia, CA), respectively.
Nearly full-length HIV-1 genome sequencing was performed as previously described. 30, 31 Sequences were manually aligned with reference strains of relevant subtypes and CRFs. 40 Phylogenetic relatedness was established using DNADIST, NEIGH-BOR, SEQBOOT, and CONSENSE, included in the PHYLIP software package version 3.2c. 41 The obtained trees were visualized using TREETOOL. 42 Bootscanning (sliding window of 300 bases) was used to confirm the genomic structures. 43 
MHAcrf02
The principle of the MHAcrf02 is to amplify short fragments along the HIV-1 genome and assess the hybridization of cladespecific fluorescent probes in a real-time PCR. 37 The amplified regions were positioned flanking recombination breakpoints that have been previously mapped on the CRF02_AG genomic structure. 7, 18 The assay is performed in a nested format. In separate first-round PCRs, five regions of the HIV-1 genome (the p24/p2/p7 part of gag, the 59 part of the RT, the RnaseH/INT part of pol, the vpu/59 extreme of gp120, and part of gp41) are amplified using universal primers (Fig. 2) . Then, each amplicon is distributed in one (in the cases of the gag and the RT re- vpu/gp120, and gp41) separate sets of second-round PCRs. Each of these reactions is performed in a Taqman real-time format, with universal primers, and fluorescent probes with specificity for subtypes A or G. When possible, CRF02_AG-specific probes are also used, taking advantage of nucleotide substitutions that distinguish the subtype A portion of CRF02_AG. Probes for each clade are used in separate real-time PCR reactions. All probes were labeled at the 59 end with 6-carboxyfluorescein (FAM) and had Black Hole Quencher (BHQ) at the 39 end (Biosource, Camarillo, CA). Probes were designed to have melting temperatures (T m ) between 61 and 66°C. Probe sequences were selected considering regions of high within-clade conservation but that contained at least three mismatches between subtypes distributed along the probe sequence. When necessary, to improve the probe specificity, a deliberate mismatch was introduced so that the probe would still hybridize to homotypic strains but not to heterotypic ones, as suggested by de Baar et al. 44 The sequences of primers and probes used in MHAcrf02 are shown on Table 1 . The first-round PCR contained GeneAmp 10X PCR Buffer (Applied Biosystems, Foster City, CA), 250 mM each dNTP, 1.5 mM MgCl 2 , 400 nM of each outer primer, 2.5 U of AmpliTaq DNA Polymerase (Applied Biosystems), and 10 ml of extracted DNA, in a final volume of 50 ml.The thermocycle routine was 1 cycle at 95°C for 10 min, then 30 cycles of 95°C 10 sec, 55°C 30 sec, and 72°C 1 min, and a final extension at 72°C for 7 min, in an ABI 9600 thermocycler. The secondround PCRs contained Taqman 2x Universal PCR Master Mix (Applied Biosystems), 400 nM of each inner primer, 250 nM probe, and 5 ml of first-round PCR product, in a final volume of 25 ml. PCR amplification was performed in a 96-well ABI PRISM 7900HT Sequence Detection System (Applied Biosystem) at 95°C 15 sec, 55°C 30 sec, and 60°C 1 min for 40 cycles. Fluorescence intensity was monitored during the reaction and was analyzed using the SDS v2.1 software (Applied Biosystem). The threshold was set based on negative controls and results were considered positive when the threshold cycle (C T ) was lower than 30 and if an exponential increase in the normalized fluorescence intensity for over five consecutive cycles was observed. Negative real-time PCR results due to lack of sample amplification were assessed by electrophoresis in a 2% agarose gel.
The lower detection limit of MHAcrf02 as determined by the reactivity of serial dilutions of HIV-1 plasmids was 7-70 input copies (data not shown).
RESULTS
Evaluated samples
The aim of this study is to develop a high-throughput assay that can distinguish CRF02_AG from other subtypes, CRFs, and URFs that circulate in West/West Central Africa. For this purpose, we assembled a panel of samples from which a virtually full-length HIV-1 sequence had been obtained and that included much of the HIV-1 diversity in the region.
In Figure 1 , 62 strains employed in the development of the assay are shown. The panel included CRF02_AG (n 5 22), the parental subtypes A (n 5 9) and G (n 5 2), as well as other clades frequently found in West/West Central Africa, such as CRF11_cpx (n 5 5), CRF13_cpx (n 5 1), subtype D (n 5 4), F2 (n 5 1), and unique recombinants between subtypes A, D, F2, G, and CRF01_AE (n 5 12). Accounting for second-generation recombinants between CRF02_AG and other subtypes that have been described, 7, 28, 29 six samples that contained 40-90% of CRF02_AG in their genomic structure were also included. The type of sample used and their countries of origin are shown in Figure 1a . The phylogenetic identity of the strains analyzed is shown on Figure 1b and c.
Design of the assay
Five regions along the HIV-1 genome that included the HIV-1 structural genes gag, pol, and env were selected based on the recombinant structure of CRF02_AG (Fig. 2) . Universal firstround PCR primers were located flanking known recombination breakpoints in CRF02_AG. Each amplicon was then distributed into several second-round PCRs, each with a clade-specific fluorescent probe, in a Taqman real-time PCR format.
In the first-round PCR, five different amplicons were generated: gag, RT, pol I/II, vpu/gp120, and gp41 I/II. In the cases of pol I/II, vpu/gp120, and gp41 I/II, each amplicon was then distributed into two separate sets of real-time PCRs (pol I and pol II, vpu and gp120, and gp41 I and gp41 II, respectively), each with its own set of inner primers. In that way the genotype at each side of the recombination breakpoint could be assessed. The gag and RT amplicons were each distributed into a single set of corresponding real-time PCRs (gag and RT, respectively). Thus, eight different sets of second-round real-time PCRs were designed.
In the second-round PCRs, 16 fluorescent probes that had specificity for clades A or G were used. In addition to that, two CRF02_AG-specific probes were designed based on the differences that exist within the clade A radiation between the CRF02_AG lineage and other lineages (i.e., CRF01_AE and East African subtype A). 7, 18 As a consequence of this, 18 probes were designed. Each probe was used in a separate PCR.
In all the cases, inner and outer primers were placed in areas of high sequence conservation between subtypes, whereas the probes were located in regions of high within-clade conservation but high between-subtype divergence. The inclusion of mixed bases was kept to a minimum and limited to the cases when it was necessary to increase the universality of the primers or the sensitivity of the probes. The nucleotide sequences of outer and inner primers and probes are shown in Table 1 .
Performance of MHAcrf02 on the tested panel
The performance of the MHAcrf02 was assessed on a panel of 62 samples. The overall rate of reactivity for the eight regions tested was 467/496 (94.15%). When each of the amplified regions was assessed separately, the PCR reactivity was 87, 97, 97, 89, 95, 97, 91, and 89% for gag, RT, pol I, pol II, vpu, gp120, gp41 I, and gp41 II, respectively. No statistically significant difference was found between the PCR reactivity for CRF02_AG samples when compared to the other subtypes and recombinant forms. In pattern recognition-based assays such as MHAcrf02, the number of reactive PCRs per sample is also important. In the current assay, 54/62 samples (87%) had at least KIJAK ET AL. 524 Figure 3a . The 22 CRF02_AG strains shared a pattern consistent with the structure of CRF02_AG: they reacted with probes GAG-02, GAG-A, RT-G, POLI-A, POLII-G, VPU-G, GP120-02, GP41I-A, and GP41II-G (which will be referred to as "homologous" probes), and they did not react with probes GAG-G, RT-A, POLI-G, POLII-A, VPU-A, GP120-A, GP120-G, GP41I-G, and GP41II-A (which will be referred to as "heterologous" probes). Within the CRF02_AG cluster, minor deviations from this pattern were observed and were caused by failure in PCR, lack of "homologous"-probe reactivity, or unexpected reaction with "heterologous" probes, as previously reported for other MHA systems. 37 In the case of "second-gen-KIJAK ET AL. 526 eration" recombinants, parts of the CRF02_AG pattern were conserved, which allow for the characterization of these strains as related to CRF02_AG. The CRF02_AG probe-reactivity pattern was specific for this clade and different from that of parental subtypes A and G, and other relevant subtypes, CRFs and URFs (Fig. 3a) . Note that a level of reactivity for non-CRF02_AG samples with "homologous" probes is expected, for example, subtype A samples are expected to react with three "homologus" probes (i.e., GAG-A, POLI-A, and GP41I-A) and five "heterologous" probes (i.e., RT-A, POLII-A, VPU-A, GP120-A, and GP41II-A). Other subtypes, CRFs, and URFs may react with a number of "homologous" and "heterologous" probes depending on the A-or Gsubtype genomic content and the homology with MHAcrf02 probes.
The analysis of the specificity of the MHAcrf02 probe system for CRF02_AG is shown on Figure 3b . For 22 CRF02_AG samples, the average reactivity with "homologous" probes was 88% (range: 68-100%), while the average reactivity with "heterologous" probes was 4% (range: 0-18%).
Establishment of criteria for identification of CRF02_AG by MHAcrf02
To clearly establish a criterion for classifying a sample as CRF02_AG or a CRF02_AG-containing recombinant, an analysis of the number of "homologous" and "heterologous" probes reacting in samples of different clades was carried out. In Figure 4 , two separate groups were defined. On the one hand, CRF02_AG samples and CRF02_AG-containing recombinants grouped together in a region defined by four to nine reactive "homologous" probes and zero to two "heterologous" probes. Within this group, three subclusters were defined based on their PCR and probe reactivity in MHAcrf02 and their genomic structure: CRF02_AG with eight reacting PCRs (n 5 17), CRF02_AG with five to seven reacting PCRs (n 5 5), and CRF02_AG-containing recombinants (n 5 6). The samples in the first subgroup reacted with seven to nine "homologous" and zero to two "heterologous" probes. In the second group, the lack of reactivity at the PCR level prevented the sample from hybridizing to the probes, as reflected in the lower number of reacting "homologous" probes observed (range 5 7-5). In the CRF02_AG-containing recombinants, a trend for samples with a lower content for CRF02_AG in their genomic structure toward lower numbers of reacting "homologous" probes was observed. Importantly, samples from all the other subtypes, CRFs, and unique recombinants clustered separately from the CRF02_AG. In no case did any non-CRF02_AG sample react simultaneously with more than three "homologous" and less that three "heterologous" probes. No clear identification of individual non-CRF02_AG clades could be established based on the number of reacting "homologous" and "heterlogous" probes, even though a trend could be observed (i.e., subtype A samples reacted with one to three "homologous" and four to five "heterologous" probes, subtype G reacted with four "homologous" and four "heterlogous" probes, data not shown).
Thus, we could clearly establish a cut-off for the genotyping of a sample by MHAcrf02: only samples that reacted simultaneously with four or more "homologous" and two or less "heterologous" probes would be classified as CRF02_AG or CRF02_AG-containing recombinants. Based on this classification, the MHAcrf02 would perform with a sensitivity and specificity of 100%. The system proved to be so robust that neither the lack of reaction in some PCRs nor the recombination of CRF02_AG with other clades interfered with the classification.
DISCUSSION
The aim of present work was to design a genotyping tool to aid the evaluation of the HIV-1 epidemics in West/West Central Africa in the setting of large cohorts. The results presented in this paper clearly indicate that MHAcrf02 meets the requirements for such a tool. First, MHAcrf02 allows for the specific detection of CRF02_AG and CRF02_AG-containing recombinants in a milieu of other complex strains, including the parental subtypes A and G, other subtypes, CRFs, and URFs. None of the 34 non-CRF02_AG samples assessed was classified as CRF02_AG by this assay. High throughput, a crucial characteristic in tests aimed at the analysis of large cohorts, can also be achieved through MHAcrf02 because of the use of the PCR and real-time PCR technologies. 37 With this assay, a trained technician having all the necessary resources could test ca. 100 samples in a week. In addition, MHAcrf02 is applicable to primary clinical samples. The performance of the test on primary PBMCs was comparable to that observed on HIV-1 clones and cocultures (data not shown). When preceded by a retrotranscription step, the assessment of plasma HIV-1 RNA samples showed results equivalent to those of primary PBMCs (data not shown). Finally, MHAcrf02 performed with high specificity and sensitivity.
MHAcrf02, as any other genotyping method, has its limitations. The use of this assay is restricted to the study of the West/West Central African samples for which it was specifically designed. Other regional MHAs have been developed, such as MHAacd in East Africa, 37 MHAbf in South America, 38 or MHAbce in Southeast Asia. 39 Another limitation is HIV-1 within-clade genetic diversity, which may prevent, in some cases, the hybridization of primers and probes. In the current study, failure in the PCR amplification and probe binding was observed, but in no case did it compromise the clear classification of the samples. Furthermore, using the criteria for identification proposed here, CRF02_AG samples with up to 3/8 negative PCRs were also successfully identified. HIV-1 genetic diversity could also lead to the hybridization of probes to heterotypic strains, decreasing the specificity. In the present analysis, as the criteria of classification relied on the recognition of patterns of probe reactivity rather than the reactivity at a single or few loci, high specificity was achieved. The assessment of both "homologous" and "heterologous" probes allowed for the specific sorting out of CRF02_AG strains be it from parental or from unrelated clades, and it rendered MHAcrf02 a capacity to cope with the extensive HIV-1 genetic diversity found in the region. Moreover, the location of the probes at both sides of established recombination breakpoints in CRF02_AG minimizes false positive results due to A/G intersubtype recombinants phylogenetically unrelated to the CRF.
The emergence of second-generation recombinants between CRF02_AG and other clades is a phenomenon that should also be monitored. 7, 28, 29 These recombinants may share epitopes and other biologically relevant properties with the parental CRF, while losing some of the motifs that react with MHAcrf02 "homologous" probes. The performance of this assay was tested on a set of second-generation recombinants with a CRF02_AG genetic content ranging from 40 to 90%, and a varying level of loss of recognition by "homologous" probes was observed. However, 6/6 samples were successfully identified as CRF02_AG-related, still reacting with a number of "homologous" and "heterologous" probes that clearly differentiated them from non-CRF02_AG strains. Nevertheless, it is expected that strains with an even lower genetic content of CRF02_AG may not be identified by this assay. The analysis of larger numbers of samples will provide a deeper insight into the performance of the assay.
The mosaic genomic structure of CRF02_AG 7,18 on the one hand, and the level of complexity and extent of the HIV-1 epidemics in West/West Central 7,18 on the other, seem to pose conflicting methodological requirements for genotyping tools. No other assay except for full-length genome (FLG) nucleotide sequencing, a low-throughput sophisticated technique, can be used to accurately establish the genotype of strains in this region of the world. 7, 18 Cohort-based studies require the use of high-throughput assays to obtain adequate sampling of strains. The MHAcrf02 assay can bridge this gap. MHAcrf02 and FLG sequencing share the extensive examination of different areas of the HIV-1 genome, while the former has a much larger throughput. Nevertheless, MHAcrf02 is not meant to replace FLG sequencing, rather it can be useful for the screening of large numbers of samples and for selecting either interesting specimens or a representative sample set for FLG sequencing.
Other approaches applied to this problem have included partial-genome sequencing 5, 6, 8, 10, 12, 33 and HMA. 25, [34] [35] [36] The latter, in its gag/env version, acknowledged the need to differentiate CRF02_AG from subtype A and CRF01_AE. 35 In addition to its higher throughput, MHAcrf02 presents another advantage over partial sequencing and HMA: by assessing simultaneously eight different HIV-1 genomic regions, MHAcrf02 is less prone to false positive results due to A/G recombinants unrelated to CRF02_AG.
CRF02_AG is recognized as one of the six clades most globally prevalent in the HIV-1/AIDS pandemic, together with sub-types A, B, C, D, and CRF01_AE. 7, 18 It has been selected for use in candidate HIV-1 vaccines. This assay will permit more efficient characterization of the region, countries, and cohorts where CRF02_AG is an important strain. Together with other regional genotyping assays, MHAcrf02 will contribute to the development of a global picture of the HIV-1 diversity and geographic distribution, providing a strong foundation for intervention. The first broad field test of this assay is underway.
